<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>BioCardia ( (BCDA) ) has issued an announcement. On May 8, 2026, BioCardia reported that a Pre-Submission Meeting with the FDA produced agreement on two potential marketing clearance pathways for its Helix Transendocardial Delivery Catheter System. The agency raised no concerns about Helix’s safety, performance or compatibility, signaled a preference for approval in tandem with BioCardia’s CardiAMP Cell Therapy for heart failure, and indicated that a follow-on submission could support a De Novo clearance route. Helix is designed as a minimally invasive platform for targeted intramyocardial delivery of therapeutic and diagnostic agents, using a specialized helical needle to reach heart regions that other delivery methods cannot. BioCardia’s management said an independent Helix clearance could enhance development and commercial partnerships for emerging cell, gene and protein therapies, potentially strengthening the company’s position as a delivery partner in advanced cardiovascular therapeutics. CardiAMP Cell Therapy, already granted FDA Breakthrough designation, leverages patients’ own bone marrow cells in a catheter-based procedure to boost capillary density and curb fibrosis in myocardial tissue. The program’s progress, supported by public funding and reimbursement and reinforced by positive signals from Japan’s PMDA on existing trial data, underpins BioCardia’s broader strategy to integrate its therapeutic platforms with enabling delivery technologies like Helix. The most recent analyst rating on (BCDA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page. Spark’s Take on BCDA Stock According to Spark, TipRanks’ AI Analyst, BCDA is a Neutral. The score is held down primarily by very weak financial performance (persistent losses and material cash burn with limited cash), reinforced by a weak technical trend. This is partially offset by a reasonably constructive earnings update and positive recent regulatory/IP milestones that create near-term catalysts, while valuation signals are limited due to negative earnings. To see Spark’s full report on BCDA stock, click here. More about BioCardia BioCardia, Inc., based in Sunnyvale, Calif., is a global leader in cellular and cell-derived therapeutics targeting cardiovascular and pulmonary disease. Its pipeline centers on CardiAMP autologous and CardiALLO allogeneic cell therapies, supported by proprietary Helix biotherapeutic delivery, Morph vascular navigation and the upcoming Heart3D fusion imaging platforms, with three cardiac clinical-stage candidates and selective partnering on biologic delivery. BioCardia’s CardiAMP Cell Therapy, which has FDA Breakthrough designation, uses a patient’s own bone marrow cells delivered via a minimally invasive catheter procedure to improve microvascular function in ischemic heart failure. The program’s clinical development is backed by the Maryland Stem Cell Research Fund and benefits from reimbursement by the Centers for Medicare and Medicaid Services, while Japanese regulators have indicated existing trial data may be sufficient to support an approval filing. Average Trading Volume: 63,586 Technical Sentiment Signal: Sell Current Market Cap: $11.93M </div>

BCDA

BioCardia has announced FDA agreement on two marketing clearance pathways for its Helix Transendocardial Delivery Catheter System, with no safety concerns raised. The Helix system aims for targeted delivery of therapies for heart failure, potentially enhancing partnerships in advanced cardiovascular treatments. The CardiAMP Cell Therapy, leveraging patients' bone marrow cells, has FDA Breakthrough designation. Despite a recent Buy rating for BCDA stock, Spark's AI Analyst rates it as Neutral due to weak financial performance and cash burn, though recent regulatory milestones provide near-term catalysts.

BioCardia Secures FDA Pathways for Helix Catheter System